ARTV

Artiva Biotherapeutics, Inc.

Fundamental data last updated:September 4, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

 


Analyze ARTV on TradingView

VALUATION

P/E

-2.19

Market Cap ($M USD)

$190.69M

Forward P/E

-6.95

PEG

-0.10

PRICE TO SALES

0.00

PRICE TO BOOK

2.17

EV / EBITDA

-2.01

5-Year Average P/E

Free Cash Flow Yield

-42.05%

DCF Value

$0.64

Graham Number

N/A

Price to FCF

-2.38

EV to FCF

-2.24

Earnings Yield

-45.73%

FCF Yield

-42.05%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$3.53

Next Year EPS Growth Estimate

-$1.11

Next Year Revenue Growth Estimate

$207.25M

Return on Equity (ROE)

-73.16%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.10

Piotroski F-Score

1

Altman Z-Score

-0.38

Return on Invested Capital (ROIC)

-96.84%

Current Ratio

8.16

Quick Ratio

8.16

Net Debt to EBITDA

0.12

Interest Coverage

0.00

Gross Profit margin

0.00%

FCF PER SHARE

$-3.25

REVENUE PER SHARE

$0.00

Analyze ARTV on TradingView

Gainseekers Quantitative Analysis

Summary

ARTV Artiva Biotherapeutics, Inc. is a perplexing case of valuation misalignment. Despite a mean consensus target price of $35.00, the stock has traded significantly below its DCF value, suggesting a potential mispricing. However, the Forward P/E of -9.37 and a dismal Earnings Yield of -32.40% paint a picture of financial distress. The Altman Z-score of 2.23 indicates moderate risk of bankruptcy, raising questions about its long-term viability. This is a high-risk, high-reward scenario that demands careful consideration.

AI Exposure / Tech Reliance

In the rapidly evolving biotechnology sector, Artiva Biotherapeutics is well-positioned to leverage AI advancements for drug discovery and personalized medicine. The company's focus on innovative therapies aligns with modern tech shifts, potentially enhancing its R&D efficiency. However, execution will be key to capitalizing on these opportunities.

The Bull Case

For the optimistic investor, Artiva's low Debt/Equity ratio of 0.10 and robust Current Ratio of 8.16 suggest a solid liquidity position. Despite a negative ROIC of -96.84%, the company's ability to maintain operations without significant debt is noteworthy. The biotech sector's growth potential, coupled with a consensus "Buy" rating, provides a compelling narrative for those seeking high-risk, high-reward opportunities.

The Bear Case

Artiva's financials reveal glaring weaknesses, particularly its negative Price to FCF of -3.36 and a Piotroski F-Score of 1, indicating poor operational efficiency. The stock's proximity to its 52-week high, with a 33.43% distance, suggests it may be technically overextended. With no revenue per share and a negative EPS, the company struggles to demonstrate profitability, making it a risky bet for cautious investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$37.50

Institutional Ownership %

1-Year Beta

2.87

Insider Buying % (6 Mo)

Distance to 52-Week High

88.33%

Distance to 52-Week Low

80.95%

EARNINGS SURPRISE %

-7.95%

50-DAY SMA

$8.67

200-DAY SMA

$5.11

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.